Johnson & Johnson (NYSE: JNJ) has agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion.
To read the entire story, you must be logged in.
Please log in now or register with us.
